Controversy debate: Neoadjuvant vs adjuvant therapy in advanced melanoma

The use of neo-adjuvant therapy as standard care in people with locoregional and oligometastatic melanoma looks promising but it is not yet ready for prime time, concludes a ‘controversy’ debate that pitted neo-adjuvant against adjuvant or combination therapy.  At the opening of the session ESMO 2019 delegates were asked if neoadjuvant therapy in patients with ...

Already a member?

Login to keep reading.

© 2022 the limbic